BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-4.07%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$8.61B
AUM Growth
-$1.09B
(-11%)
Cap. Flow
-$379M
Cap. Flow
% of AUM
-4.4%
Top 10 Holdings %
Top 10 Hldgs %
30.78%
Holding
207
New
16
Increased
51
Reduced
80
Closed
30
Top Buys
| 1 |
Outset Medical
OM
|
$66.1M |
| 2 |
Boston Scientific
BSX
|
$42.1M |
| 3 |
CareDx
CDNA
|
$31.2M |
| 4 |
Pacific Biosciences
PACB
|
$30.3M |
| 5 |
Aurinia Pharmaceuticals
AUPH
|
$29.8M |
Top Sells
| 1 |
Biogen
BIIB
|
$106M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$81.3M |
| 3 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
$75.3M |
| 4 |
Danaher
DHR
|
$68.9M |
| 5 |
Humana
HUM
|
$68M |
Sector Composition
| 1 | Healthcare | 98.39% |
| 2 | Industrials | 0.69% |
| 3 | Energy | 0.03% |
| 4 | Technology | 0.01% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Zimmer Biomet
ZBH
$20.8B
| $34.6M | 0.4% |
270,734
-8,592
| -3% | -$1.1M |
|
77
Veeva Systems
VEEV
$44.4B
| $34.1M | 0.4% |
160,601
-4,354
| -3% | -$925K |
|
78
Beam Therapeutics
BEAM
$1.9B
| $33.4M | 0.39% |
582,821
-30,000
| -5% | -$1.72M |
|
79
HUTCHMED
HCM
$2.62B
| $33.1M | 0.38% |
1,750,690
+673,820
| +63% | +$12.7M |
|
80
ESSA Pharma
EPIX
$11.2M
| $31.1M | 0.36% |
5,034,814
| – | – |
|
|
81
Aurinia Pharmaceuticals
AUPH
$1.58B
| $29.8M | 0.35% |
+2,405,825
| New | +$29.8M |
|
82
Axsome Therapeutics
AXSM
$6.09B
| $29.8M | 0.35% |
719,482
+67,545
| +10% | +$2.8M |
|
83
Scholar Rock
SRRK
$3.3B
| $28.2M | 0.33% |
2,184,425
-110,000
| -5% | -$1.42M |
|
84
Illumina
ILMN
$15.2B
| $27.6M | 0.32% |
81,090
+3,856
| +5% | +$1.31M |
|
85
Castle Biosciences
CSTL
$673M
| $27.3M | 0.32% |
+607,614
| New | +$27.3M |
|
86
Generation Bio
GBIO
$40.3M
| $27M | 0.31% |
368,218
-19,000
| -5% | -$1.39M |
|
87
Teladoc Health
TDOC
$1.37B
| $26.2M | 0.3% |
363,216
| – | – |
|
88
Nektar Therapeutics
NKTR
$543M
| $25.9M | 0.3% |
320,560
+23,780
| +8% | +$1.92M |
|
89
Legend Biotech
LEGN
$6.64B
| $24M | 0.28% |
660,069
+2,413
| +0.4% | +$87.7K |
|
90
CVS Health
CVS
$93B
| $23.5M | 0.27% |
232,355
+3,557
| +2% | +$360K |
|
91
Hologic
HOLX
$14.7B
| $21.2M | 0.25% |
275,783
-303,641
| -52% | -$23.3M |
|
92
ResMed
RMD
$39.4B
| $20.9M | 0.24% |
86,349
-141
| -0.2% | -$34.2K |
|
93
Esperion Therapeutics
ESPR
$490M
| $19.9M | 0.23% |
4,299,164
-220,000
| -5% | -$1.02M |
|
94
10x Genomics
TXG
$1.66B
| $19.2M | 0.22% |
252,859
+20,187
| +9% | +$1.54M |
|
95
BioNTech
BNTX
$24.1B
| $19.1M | 0.22% |
111,766
-1,700
| -1% | -$290K |
|
96
Avantor
AVTR
$8.74B
| $17.3M | 0.2% |
512,216
| – | – |
|
|
NVRO
97
DELISTED
NEVRO CORP.
NVRO
| $17.2M | 0.2% |
237,841
| – | – |
|
98
Mersana Therapeutics
MRSN
$34.8M
| $15.8M | 0.18% |
158,160
-8,400
| -5% | -$838K |
|
99
Transmedics
TMDX
$3.65B
| $15.7M | 0.18% |
581,029
| – | – |
|
100
Phreesia
PHR
$1.81B
| $15.3M | 0.18% |
580,498
-11,829
| -2% | -$312K |
|